Assess for gestational diabetes mellitus
This tool was developed based on the 2018 Diabetes Canada Clinical Practice Guidelines for the Prevention and Management of Diabetes. Published every five years, these guidelines represent the best and most current evidence-based clinical practice data for healthcare professionals.
Hyperglycemia in pregnancy is teratogenic. At conception and during the first trimester, hyperglycemia increases the risk of fetal malformations and intrauterine fetal demise. Later in pregnancy, it increases the risk of macrosomia, fetal and infant death as well as metabolic and obstetrical complications at birth.
Therefore all pregnant women without known pre-existing diabetes should be screened for gestational diabetes between 24 to 28 weeks of pregnancy. In women at high risk of undiagnosed type 2 diabetes, early screening (<20 weeks) with an A1C/FPG should be done to identify potentially pre-existing diabetes. See Chapter 4: Screening for Diabetes in Adults - Table 1: Risk factors for type 2 diabetes for more detailed information.
There are two approaches for the screening and diagnosis of GDM at 24-28 weeks:
Preferred Approach - 2 steps
A 50g Glucose Challenge Test (GCT) administered in the nonfasting state with plasma glucose (PG) measured 1 hour later.
If the GCT screen is positive, a 75g OGTT should be performed as the diagnostic test for GDM using 1 of the following criteria:
Alternative Approach - 1 step
A 75 g OGTT should be performed (with no prior screening 50g GCT) as the diagnostic test for GDM using 1 of the following criteria:
These two approaches are summarized in this flow chart
Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., and Sanghera, R.
Risk factors for type 2 diabetes:
• Age ≥40 years
• First-degree relative with type 2 diabetes
• Member of high-risk population (e.g. African, Arab, Asian, Hispanic, Indigenous or South Asian descent, low socioeconomic status)
• History of prediabetes (lGT, lFG or A1C 6.0%–6.4%)
• History of GDM
• History of delivery of a macrosomic infant
• Presence of end organ damage associated with diabetes:
◦ Microvascular (retinopathy, neuropathy, nephropathy)
◦ CV (coronary, cerebrovascular, peripheral)
• Presence of vascular risk factors:
◦ HDL-C <1.0 mmol/L in males, <1.3 mmol/L in females
◦ TG ≥1.7 mmol/L
◦ Hypertension
◦ Overweight
◦ Abdominal obesity
◦ Smoking
• Presence of associated diseases:
◦ History of pancreatitis
◦ Polycystic ovary syndrome
◦ Acanthosis nigricans
◦ Hyperuricemia/gout
◦ Non-alcoholic steatohepatitis
◦ Psychiatric disorders (bipolar disorder, depression, schizophrenia)
◦ HlV infection
◦ Obstructive sleep apnea
◦ Cystic fibrosis
• Use of drugs associated with diabetes:
◦ Glucocorticoids
◦ Atypical antipsychotics
◦ Statins
◦ Highly active antiretroviral therapy
◦ Anti-rejection drugs
This tool was developed based on the 2018 Diabetes Canada Clinical Practice Guidelines for the Prevention and Management of Diabetes. Published every five years, these guidelines represent the best and most current evidence-based clinical practice data for healthcare professionals.
Hyperglycemia in pregnancy is teratogenic. At conception and during the first trimester, hyperglycemia increases the risk of fetal malformations and intrauterine fetal demise. Later in pregnancy, it increases the risk of macrosomia, fetal and infant death as well as metabolic and obstetrical complications at birth.
Therefore all pregnant women without known pre-existing diabetes should be screened for gestational diabetes between 24 to 28 weeks of pregnancy. In women at high risk of undiagnosed type 2 diabetes, early screening (<20 weeks) with an A1C/FPG should be done to identify potentially pre-existing diabetes. See Chapter 4: Screening for Diabetes in Adults - Table 1: Risk factors for type 2 diabetes for more detailed information.
There are two approaches for the screening and diagnosis of GDM at 24-28 weeks:
Preferred Approach - 2 steps
A 50g Glucose Challenge Test (GCT) administered in the nonfasting state with plasma glucose (PG) measured 1 hour later.
If the GCT screen is positive, a 75g OGTT should be performed as the diagnostic test for GDM using 1 of the following criteria:
Alternative Approach - 1 step
A 75 g OGTT should be performed (with no prior screening 50g GCT) as the diagnostic test for GDM using 1 of the following criteria:
These two approaches are summarized in this flow chart
Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., and Sanghera, R.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
